Cryo‑Cell International reported consolidated revenue of $31.6 million for the year ended November 30, 2025, a 1 % decline from $32.0 million in 2024. The drop was driven by a $54,000 decline in product revenue and a $237,000 decline in public banking revenue, reflecting a 20 % reduction in new domestic cord blood specimens processed and a sharp contraction in public inventory sales.
Net income for the year was a loss of $2.4 million, or $0.30 per basic and diluted share, compared with a net income of $402,000 ($0.05 per share) in 2024. The loss was largely attributable to a $4.4 million impairment charge recorded in the fourth quarter to write down the value of public inventory to net realizable value. The impairment charge, combined with the revenue decline, pushed the company into a loss for the first time in the past two years.
Analysts had projected revenue of $31.5 million and earnings of $0.07 per share. Cryo‑Cell’s revenue of $31.6 million slightly exceeded expectations by $0.1 million, while the EPS of –$0.30 missed consensus by $0.37. The beat in revenue was modest, but the loss in earnings underscores the impact of the one‑time impairment and the weaker public banking segment.
The results highlight the ongoing financial pressure from the unresolved dispute with Duke University, which has led to inventory write‑downs and halted expansion plans. Cryo‑Cell’s focus remains on its core private cord blood storage business, and the company is working to resolve the litigation while maintaining operations in its three segments: private storage, PrepaCyte® system manufacturing, and public storage. The impairment charge and revenue decline signal short‑term headwinds, but the company’s continued emphasis on core services suggests a strategy to stabilize cash flow and rebuild profitability.
No forward guidance was disclosed for fiscal 2026, leaving investors to assess the company’s trajectory based on the current year’s performance and the status of the Duke litigation. The earnings loss and inventory write‑down indicate a need for cost discipline and a potential shift in resource allocation toward the private storage segment, which remains the company’s primary revenue generator.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.